Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.
Wall Street Technician Declares Financials, Industrials, and Biotech Poised for Breakouts. 3 ETFs Could Soar.
Markets are hunting for new leadership as the Big Tech engine sputters, and one Wall Street technician thinks she knows where the baton is being passed.
XBI: A "Hidden" ETF Up +70% In 1 Year.
State Street SPDR S&P Biotech ETF (XBI) has delivered over 75% 1-year performance, driven by equal-weight exposure to volatile small- and mid-cap biotech stocks. XBI's high beta profile offers strong upside in bullish healthcare cycles but exposes investors to elevated annualized volatility of around 26%. Current valuations for XBI are relatively stretched, with forward P/E at 17x and earnings growth expectations below 3%, making new entry less attractive.
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.
SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength
XBI continues to strengthen following a multi-month breakout, with bullish trend signals supporting upside targets near key Fibonacci retracement resistance levels.
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded.
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
The biotech industry has been a robust roller-coaster over the last half decade.
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The State Street SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
XBI: Biotech M&A Has Been Hot, But Price Trends Have Cooled
I reiterate a Hold rating on State Street SPDR S&P Biotech ETF due to fair valuation and mixed technicals. XBI's recent outperformance has faded, with higher interest rates and a less risk-on market weighing on absolute and relative strength. At 19.3x P/E and just 3.2% long-term EPS growth, XBI lacks compelling value or growth catalysts near term.
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.
Biotech ETF (XBI) Hits New 52-Week High
XBI surges to a 52-week high, nearly doubling from its low, fueled by biotech momentum, AI adoption and easing macro trends.
